Medical Center - University Of Freiburg
- Address
- lock Available on a paid plan
Stroke Prevention in Atrial Fibrillation
The Medical Center - University Of Freiburg conducts research in cardiovascular diseases, focusing on atrial fibrillation and the risk of stroke. Current studies compare the novel anticoagulant asundexian with the established therapy apixaban to determine efficacy and safety.
- Comparison of new anticoagulant with standard therapy
- Evaluation of major bleeding outcomes
- Overall benefit‑risk assessment for stroke prevention
Twelve investigators are involved in these trials, aiming to improve treatment options for patients at high risk of stroke.
Self‑Administered Treatment for Acute Myocardial Infarction
In the field of cardiovascular disease, the site evaluates the rapid‑action drug selatogrel when patients self‑administer it at the onset of symptoms suggestive of an acute myocardial infarction. The goal is to demonstrate that early, patient‑initiated therapy can reduce recurrent heart attacks.
- Patient‑initiated drug delivery
- Early recognition of heart attack symptoms
- Impact on rates of recurrent myocardial infarction
The trial involves a multidisciplinary team of cardiologists and pharmacologists working to enhance emergency care for heart attack patients.
Lipoprotein(a) Targeting in Atherosclerotic Cardiovascular Disease
Research at the center also addresses atherosclerotic cardiovascular disease with elevated lipoprotein(a) levels. The investigational agent olpasiran is being tested for its ability to lower Lp(a) and reduce major cardiovascular events such as coronary heart disease death and urgent revascularization.
- Lp(a) lowering strategy
- Effect on coronary heart disease mortality
- Potential to decrease need for urgent revascularization
This study seeks to provide new therapeutic options for patients with high cardiovascular risk linked to Lp(a) elevation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Universitaetsspital Basel2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Universitaetsspital Basel2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center - University Of Freiburg
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Effect of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a): A Randomized, Placebo-Controlled Study | Amgen Inc. | Phase III | Not Recruiting | May 2023 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 1 | Unknown | 2022-11-24 | 2022-11-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.